Current status and progress of immunotherapy for peritoneal metastatic colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2023.02.003

Abstract

Abstract:

Colorectal cancer (CRC) remains the second highest incidence and the fourth highest mortality rate among malignant tumors in China. Surgery, radiotherapy and chemotherapy significantly improve the prognosis of CRC patients, but the prognosis will be poor when peritoneal metastasis occurs. In recent years, with the breakthrough of basic medicine and the acceleration of clinical drug transformation, immunotherapy has become increasingly important and showed great potential in the treatment of peritoneal metastatic CRC. This article summarized the immunotherapy of peritoneal metastatic CRC at home and abroad in recent years.

Key words: Colorectal neoplasms, Peritoneal metastasis, Immunotherapy

Hongsheng Fang, Ruiqi Gu, Guoxiang Cai. Current status and progress of immunotherapy for peritoneal metastatic colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 107-111.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2023.02.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2023/V12/I02/107

References 50

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Riihimäki M, Hemminki A, Sundquist J, et al. Patterns of metastasis in colon and rectal cancer [J]. Sci Rep, 2016, 6: 29765.
[3]	Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3): 263-267.
[4]	Sánchez-hidalgo JM, Rodríguez-ortiz L, Arjona-sánchez Á, et al. Colorectal peritoneal metastases: Optimal management review[J]. World J Gastroenterol, 2019, 25(27): 3484-3502.
[5]	Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer[J]. J Clin Med, 2018, 7(12): 567.
[6]	Capobianco A, Cottone L, Monno A, et al. The peritoneum: healing, immunity, and diseases[J]. J Pathol, 2017, 243(2): 137-147.
[7]	Cortés-guiral D, Hübner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies[J]. Nat Rev Dis Primers, 2021, 7(1): 91.
[8]	Kojima M, Higuchi Y, Yokota M, et al. Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis[J]. PLoS One, 2014, 9(2): e88018.
[9]	MikuŁa-pietrasik J, Uruski P, Tykarski A, et al. The peritoneal "soil" for a cancerous "seed": a comprehensive review of the pathogenesis of intraperitoneal cancer metastases[J]. Cell Mol Life Sci, 2018, 75(3): 509-525.
[10]	Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: Challenges and prospective[J]. World J Gastroenterol, 2016, 22(28): 6362-6372.
[11]	Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review[J]. JAMA, 2021, 325(7): 669-685.
[12]	中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专委会. 结直肠癌腹膜转移诊治中国专家共识(2022版)[J/OL]. 中华结直肠疾病电子杂志, 2022, 11(4): 265-271.
[13]	Ganesh K, Stadler Z K, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
[14]	Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 [J]. J Clin Oncol, 2020, 38(1): 11-19.
[15]	Overman MJ, Mcdermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2017, 18(9): 1182-1191.
[16]	André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23): 2207-2218.
[17]	Network NCC. (NCCN) Clinical Practice Guidelines in Oncology. Colon Cancer, Version 2. 2022. [J]. NCCN, 2022.
[18]	Berek JS, Knapp RC, Hacker NF, et al. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum[J]. Am J Obstet Gynecol, 1985, 152(8): 1003-1010.
[19]	Berek JS. Intraperitoneal adoptive immunotherapy for peritoneal cancer[J]. J Clin Oncol, 1990, 8(10): 1610-1612.
[20]	Steis RG, Urba WJ, Vandermolen LA, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity [J]. J Clin Oncol, 1990, 8(10): 1618-1629.
[21]	Nash AM, Jarvis MI, Aghlara-fotovat S, et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors [J]. Sci Adv, 2022, 8(9): eabm1032.
[22]	Miller AM, Lemke-miltner CD, Blackwell S, et al. Intraperitoneal CMP-001: A novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer [J]. Ann Surg Oncol, 2021, 28(2): 1187-1197.
[23]	Jiang T, Zhang H, Li Y, et al. Intraperitoneal injection of class A TLR9 agonist enhances anti-PD-1 immunotherapy in colorectal peritoneal metastases [J]. JCI Insight, 2022, 7(20): e160063.
[24]	Lee SJ, Yang H, Kim WR, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer[J]. J Immunother Cancer, 2021, 9(6): e002195.
[25]	Zhao Z, Zheng L, Chen W, et al. Delivery strategies of cancer immunotherapy: recent advances and future perspectives [J]. J Hematol Oncol, 2019, 12(1): 126.
[26]	Saxena M, Van Der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378.
[27]	Harrington K, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment [J]. Nat Rev Drug Discov, 2019, 18(9): 689-706.
[28]	Alkayyal AA, Tai LH, Kennedy MA, et al. NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an Il12-expressing maraba virus cellular vaccine[J]. Cancer Immunol Res, 2017, 5(3): 211-221.
[29]	Lee YS, Lee WS, Kim CW, et al. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer[J]. J Immunother Cancer, 2020, 8(2): e000857.
[30]	Lauer UM, Schell M, Beil J, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis[J]. Clin Cancer Res, 2018, 24(18): 4388-4398.
[31]	Zamarin D, Odunsi K, Zsiros E, et al. Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results [J]. Journal of Clinical Oncology, 2022, 40(suppl. 16): 2600.
[32]	Pouget JP, Navarro-teulon I, Bardiès M, et al. Clinical radioimmunotherapy--the role of radiobiology [J]. Nat Rev Clin Oncol, 2011, 8(12): 720-734.
[33]	Kinuya S, Li XF, Yokoyama K, et al. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy[J]. Cancer Sci, 2003, 94(7): 650-654.
[34]	Schoffelen R, Van Der Graaf WT, Sharkey RM, et al. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer [J]. J Nucl Med, 2012, 53(12): 1926-1932.
[35]	Chandler CS, Bell MM, Chung SK, et al. Intraperitoneal pretargeted radioimmunotherapy for colorectal peritoneal carcinomatosis [J]. Mol Cancer Ther, 2022, 21(1): 125-137.
[36]	Hallqvist A, Bergmark K, Bäck T, et al. Intraperitoneal α-emitting radioimmunotherapy with (211)at in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations [J]. J Nucl Med, 2019, 60(8): 1073-1079.
[37]	Modak S, Zanzonico P, Grkovski M, et al. B7H3- directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study [J]. J Clin Oncol, 2020, 38(36): 4283-4291.
[38]	Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial [J]. Int J Cancer, 2010, 127(9): 2209-2221.
[39]	Ströhlein MA, Lordick F, Rüttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial [J]. Onkologie, 2011, 34(3): 101-108.
[40]	Ströhlein MA, Heiss MM, Jauch KW. The current status of immunotherapy in peritoneal carcinomatosis [J]. Expert Rev Anticancer Ther, 2016, 16(10): 1019-1027.
[41]	Frøysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa phase 1 trial [J]. Ann Surg Oncol, 2017, 24(7): 1916-1922.
[42]	Frøysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis [J]. Eur J Surg Oncol, 2021, 47(1): 134-138.
[43]	Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy [J]. Cancer Cell, 2020, 38(4): 473-488.
[44]	Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia [J]. N Engl J Med, 2014, 371(16): 1507-1517.
[45]	Katz SC, Point GR, Cunetta M, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery [J]. Cancer Gene Ther, 2016, 23(5): 142-148.
[46]	Qian S, Villarejo-campos P, García-olmo D. The role of CAR-T cells in peritoneal carcinomatosis from gastric cancer: rationale, experimental work, and clinical applications[J]. J Clin Med, 2021, 10(21): 5050.
[47]	Ang WX, Li Z, Chi Z, et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis [J]. Oncotarget, 2017, 8(8): 13545-13559.
[48]	Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients [J]. Mol Ther, 2019, 27(6): 1114-1125.
[49]	Li Z, Chi Z, Ang WX, et al. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR [J]. Immunotherapy, 2020, 12(10): 733-748.
[50]	Newick K, O'brien S, Moon E, et al. CAR T cell therapy for solid tumors[J]. Annu Rev Med, 2017, 68(1): 39-52.

Please choose a citation manager

Content to export